ASND · Ascendis Pharma A/S
United States · RS rating 80 · As of 2026-11-03
| Price | 250.17 USD |
|---|---|
| 1-day change | +0.5% |
| RS rating (overall / 1M / 3M / 12M) | 80 / 82 / 72 / 71 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 48 / 39 / 55 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +45.0% |
| Sales growth Q/Q | +15.8% |
| Distance from 52-week high | +9.7% |
| Market cap (USD) | $13.9B |